Trust Department MB Financial Bank N A continued to hold its position in Celgene Co. (NASDAQ:CELG) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,680 shares of the biopharmaceutical company’s stock at the end of the first quarter. Trust Department MB Financial Bank N A’s holdings in Celgene were worth $707,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of the stock. PICTET BANK & TRUST Ltd raised its stake in Celgene by 16.5% in the third quarter. PICTET BANK & TRUST Ltd now owns 35,445 shares of the biopharmaceutical company’s stock valued at $3,705,000 after buying an additional 5,025 shares during the last quarter. Headinvest LLC acquired a new position in Celgene during the fourth quarter valued at $2,667,000. Sawgrass Asset Management LLC acquired a new position in Celgene during the third quarter valued at $31,970,000. Hellman Jordan Management Co. Inc. MA increased its position in Celgene by 26.7% in the third quarter. Hellman Jordan Management Co. Inc. MA now owns 14,235 shares of the biopharmaceutical company’s stock valued at $1,454,000 after buying an additional 3,000 shares during the last quarter. Finally, British Airways Pensions Investment Management Ltd increased its position in Celgene by 173.0% in the third quarter. British Airways Pensions Investment Management Ltd now owns 367,016 shares of the biopharmaceutical company’s stock valued at $38,344,000 after buying an additional 232,596 shares during the last quarter. Institutional investors and hedge funds own 77.68% of the company’s stock.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.47 by $0.21. Celgene had a return on equity of 77.95% and a net margin of 17.80%. The firm had revenue of $2.96 billion for the quarter, compared to analysts’ expectations of $3.04 billion. During the same quarter last year, the firm earned $1.32 earnings per share. The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year.
TRADEMARK VIOLATION WARNING: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.chaffeybreeze.com/2017/05/20/trust-department-mb-financial-bank-n-a-has-707000-position-in-celgene-co-celg-updated.html.
A number of research analysts have recently commented on CELG shares. Oppenheimer Holdings Inc. set a $148.00 target price on Celgene and gave the company a “buy” rating in a research report on Friday, February 17th. Cann restated a “buy” rating on shares of Celgene in a research report on Thursday, January 26th. Vetr downgraded Celgene from a “strong-buy” rating to a “buy” rating and set a $132.02 price target for the company. in a research report on Thursday, February 16th. Zacks Investment Research upgraded Celgene from a “hold” rating to a “buy” rating and set a $127.00 price target for the company in a research report on Wednesday, February 1st. Finally, BTIG Research restated a “buy” rating and issued a $138.00 price target on shares of Celgene in a research report on Monday, January 30th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $138.53.
In other Celgene news, Director Gilla Kaplan sold 14,033 shares of the business’s stock in a transaction dated Thursday, March 30th. The stock was sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the transaction, the director now owns 73,109 shares in the company, valued at $9,053,087.47. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Rupert Vessey sold 4,000 shares of the business’s stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $124.42, for a total value of $497,680.00. Following the transaction, the insider now owns 778 shares in the company, valued at approximately $96,798.76. The disclosure for this sale can be found here. Insiders sold 27,283 shares of company stock worth $3,382,386 in the last quarter. 0.97% of the stock is owned by insiders.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.